Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...